From 1 January 2024, pharmaceutical companies will be able to make a parallel application for the regulatory approval and reimbursement of certain drugs in Switzerland under an early access initiative.
Swiss To Introduce Parallel HTA & Regulatory Submissions, More Transparent Decisions
Several categories of pharmaceutical products, including those used to treat rare diseases, could be reimbursed three months faster than is typical in Switzerland under its new early access scheme.
